Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyCHRS -4.00%59 Earnings Yield (Joel Greenblatt) % is -101.01% as of Jun. 2026. GuruFocus rates CHRS with a GF Score™ of 59/100 and a GF Value™ of $1.04 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,341 Biotechnology companies, Coherus Oncology ranks worse than 89.41% on this metric.
Coherus Oncology's Enterprise Value for the quarter that ended in Jun. 2026 was $150.15 Mil.
Coherus Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-152.06 Mil. Coherus Oncology's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -101.01%.
The historical rank and industry rank for Coherus Oncology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CHRS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4818.22 Med: -23.55 Max: 1818.33
Current: -109.89
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Coherus Oncology was 1818.33%. The lowest was -4818.22%. And the median was -23.55%.
CHRS's Earnings Yield (Joel Greenblatt) % is ranked worse than 89.41% of 1341
companies
in the Biotechnology industry
Industry Median: -9.94
vs CHRS: -109.89
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Coherus Oncology's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Coherus Oncology Earnings Yield (Joel Greenblatt) % Related Terms
Coherus Oncology Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coherus Oncology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Coherus Oncologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Coherus Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-152.06 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -101.01% mean?
Coherus Oncology (CHRS) has a Earnings Yield (Joel Greenblatt) % of -101.01% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #1199 out of 1341 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Coherus Oncology's Earnings Yield (Joel Greenblatt) % too high?
Coherus Oncology's current Earnings Yield (Joel Greenblatt) % is -101.01%. Based on the distribution chart, Coherus Oncology ranks #1199 out of 1341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Earnings Yield (Joel Greenblatt) % compare to VYGR and KROS?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #1199 out of 1341 companies for Earnings Yield (Joel Greenblatt) %. This places Coherus Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Earnings Yield (Joel Greenblatt) % is -101.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.04, compared to a current price of $1.32 — trading 26.9% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -101.01%. Coherus Oncology's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current Earnings Yield (Joel Greenblatt) % is -101.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (CHRS) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of $1.32 is trading 26.9% above its estimated GF Value™ of $1.04.
GuruFocus considers Coherus Oncology to be Modestly Overvalued.
Key valuation signals for CHRS:
Earnings Yield (Joel Greenblatt) %: -101.01%
GF Value™: $1.04 vs. price of $1.32 (26.9% above fair value)
No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
59GF Score
Get the complete analysis for CHRS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHRS has been successfully added to your 
